Colorectal cancer stage III – Diagnostics – Overview of Information and Clinical Research

When colorectal cancer reaches stage III, it means the disease has moved beyond the bowel wall and spread to nearby lymph nodes, but hasn’t yet traveled to distant organs. Understanding how doctors identify and confirm this stage is essential for anyone facing this diagnosis, as the specific tests and examinations help guide treatment decisions and provide a clearer picture of what lies ahead.

Introduction: Who Should Seek Diagnostics and When

Diagnosing colorectal cancer stage III is a process that typically begins when someone experiences symptoms or when cancer is discovered during routine screening. If you notice persistent changes in your bowel habits, blood in your stool, unexplained abdominal pain, or ongoing bloating, it’s important to talk to a healthcare provider right away. These symptoms don’t automatically mean you have cancer, but they signal that something needs to be checked^[4].

People who have already undergone screening tests like colonoscopy and had cancer detected will need further diagnostic steps to determine whether the cancer has spread to nearby lymph nodes. This is what distinguishes stage III from earlier stages. Stage III colorectal cancer is defined by the presence of cancer cells in the lymph nodes, which are small bean-shaped structures that help fight infection. However, at this stage, the cancer has not yet reached distant parts of the body like the liver or lungs^[1]^[2].

Anyone over the age of 50 should consider regular screening for colorectal cancer, as this is when the risk increases. However, younger people between 20 and 49 are also increasingly being diagnosed, so if you have a family history of colorectal cancer or notice warning signs, age should not stop you from seeking evaluation^[4].

Early diagnosis matters because stage III colon cancer is still curable for many people. Depending on specific characteristics of the cancer, between 40% and 50% of patients who undergo surgery alone can be cured. However, because cancer at this stage has spread to lymph nodes, additional treatment beyond surgery is often recommended to reduce the risk of the cancer returning^[6].

Classic Diagnostic Methods Used to Identify Stage III Colorectal Cancer

Once colorectal cancer is suspected, a series of diagnostic tests help doctors confirm the diagnosis and determine whether the cancer has reached stage III. These tests examine the extent of the disease, how deeply it has grown into the bowel wall, and whether it has spread to nearby lymph nodes.

Colonoscopy and Tissue Sampling

The most important initial diagnostic tool is colonoscopy, a procedure in which a healthcare provider inserts a long, flexible tube with a camera through the rectum to examine the entire colon. This allows the doctor to see any abnormal growths or tumors directly. During the colonoscopy, the doctor can remove tissue samples or polyps for further examination^[4]^[19].

These tissue samples are sent to a laboratory for a biopsy, where specialists examine the cells under a microscope. The biopsy reveals whether the cells are cancerous, how quickly they are growing, and other characteristics that help doctors understand the cancer better. This step is essential because it confirms the presence of cancer and provides information that shapes the entire treatment plan^[19].

Imaging Tests to Assess Spread

After cancer is confirmed, imaging tests are used to determine whether the cancer has spread beyond the colon to nearby lymph nodes or other areas of the body. These tests create detailed pictures of the inside of the body and help doctors “stage” the cancer accurately.

Computed Tomography (CT) scans use X-rays taken from multiple angles to create cross-sectional images of the body. CT scans of the abdomen and pelvis are commonly used to see if the cancer has grown through the bowel wall or if lymph nodes near the colon appear enlarged, which might suggest cancer involvement^[19].

Magnetic Resonance Imaging (MRI) is another imaging method that uses magnets and radio waves instead of X-rays. MRI scans are particularly useful for rectal cancer, as they provide detailed images of soft tissues and help doctors see how far the cancer has spread into surrounding structures^[19].

In some cases, doctors may use ultrasound, which uses sound waves to create images. For rectal cancer, a special type called transrectal ultrasound can be performed during an examination to visualize the layers of the rectal wall and nearby lymph nodes^[8].

⚠️ Important

Stage III colorectal cancer is defined by the presence of cancer in nearby lymph nodes, but it has not spread to distant organs. The exact stage—whether IIIA, IIIB, or IIIC—depends on how deeply the cancer has grown into the bowel wall and how many lymph nodes contain cancer cells. This detailed staging helps doctors decide on the best treatment approach for each individual.

Blood Tests

Blood tests are not used to diagnose colorectal cancer directly, but they provide valuable information about a person’s overall health. These tests check how well organs like the kidneys and liver are functioning, which is important when planning treatment. Blood tests can also detect anemia, a low red blood cell count that might indicate internal bleeding from a tumor^[19].

A specific blood test measures a protein called carcinoembryonic antigen (CEA). Some colorectal cancers produce CEA, and measuring its level in the blood can help doctors monitor how the cancer responds to treatment. After treatment, checking CEA levels periodically can help detect if the cancer returns^[19].

Pathology Report and Final Staging

The most definitive way to determine whether colorectal cancer is stage III is through examination of tissue removed during surgery. After a surgeon removes the tumor and nearby lymph nodes, these tissues are sent to a pathologist who examines them carefully. The pathologist determines how deeply the cancer has penetrated the bowel wall and counts how many lymph nodes contain cancer cells^[6].

Stage III is divided into three subcategories—IIIA, IIIB, and IIIC—based on these findings. For example, stage IIIA means the cancer has spread through the inner layers of the bowel wall and affected one to three nearby lymph nodes, or it has reached the submucosa and affected four to six lymph nodes. Stage IIIB involves deeper penetration of the bowel wall or more lymph nodes, while stage IIIC indicates the most extensive spread within the local area^[1]^[2].

Understanding this detailed classification is important because it helps predict the likelihood of cancer returning and guides decisions about whether additional treatment, like chemotherapy, is needed after surgery.

Diagnostics for Clinical Trial Qualification

Many patients with stage III colorectal cancer are offered the opportunity to participate in clinical trials, which are research studies testing new treatments or treatment combinations. To qualify for a clinical trial, patients must undergo specific diagnostic tests to ensure they meet the study’s criteria.

Clinical trials often require confirmation of the cancer stage through pathology reports, meaning doctors need clear documentation that the cancer has spread to lymph nodes but not to distant organs. Imaging tests like CT scans or MRI are used to verify that the cancer has not metastasized beyond the local area^[2]^[14].

Some trials may also require specific laboratory tests to evaluate a patient’s overall health and organ function. This ensures that participants are healthy enough to tolerate the experimental treatment being studied. Blood tests checking kidney function, liver function, and blood cell counts are commonly required^[11].

In addition, certain clinical trials focus on specific types of colorectal cancer based on genetic or molecular characteristics. For these studies, patients may undergo specialized testing of their tumor tissue to identify genetic mutations or biomarkers. For example, tests might look for mutations in genes like KRAS or check for markers that predict how the cancer will respond to certain treatments. These tests help researchers understand which patients are most likely to benefit from new therapies^[11].

Participating in a clinical trial can provide access to cutting-edge treatments that are not yet widely available. However, not every patient will qualify, and the decision to join a trial should be made in consultation with your healthcare team, considering your individual situation and preferences.

⚠️ Important

Clinical trials for stage III colorectal cancer often test whether newer chemotherapy combinations or shorter treatment durations can improve outcomes while reducing side effects. Participating in such trials may offer access to innovative therapies, but eligibility depends on meeting specific diagnostic and health criteria established by the research study.

Prognosis and Survival Rate

Prognosis

The prognosis for stage III colorectal cancer depends on several factors, including how deeply the cancer has grown into the bowel wall, how many lymph nodes contain cancer, and whether the tumor has certain high-risk features. Patients who undergo complete surgical removal of the tumor and nearby lymph nodes, followed by chemotherapy, have a significantly better chance of long-term survival compared to those who receive surgery alone^[6].

Even after successful surgery, about half of patients with stage III colon cancer experience a recurrence because tiny amounts of cancer, called micrometastases, may have spread beyond the colon. These cancer cells are too small to be detected by any available test, which is why additional treatment with chemotherapy is often recommended. Chemotherapy aims to eliminate these hidden cancer cells and reduce the risk of the disease coming back^[6]^[11].

Several features of the cancer can affect prognosis. For instance, tumors classified as high grade, meaning the cells look very abnormal under the microscope, may be more aggressive. Other concerning features include blockage or perforation of the intestine, cancer cells found in blood vessels or nerves near the tumor, and fewer than 12 lymph nodes removed during surgery for examination^[13].

Despite these challenges, many people with stage III colorectal cancer achieve long-term survival and are cured of the disease. The addition of chemotherapy after surgery has been shown to reduce the risk of cancer recurrence and improve overall survival. The specific chemotherapy regimen used, the patient’s general health, and their ability to complete treatment all play important roles in determining outcomes^[11].

Survival Rate

Survival rates for stage III colorectal cancer provide an estimate of how many people with this stage of cancer are alive a certain number of years after diagnosis. It’s important to remember that these are general statistics and every person’s situation is unique.

For patients with stage III colon cancer who receive surgery alone, the cure rate is approximately 40% to 50%. This means that without additional treatment, roughly half of patients will experience a return of the cancer^[6].

When chemotherapy is added after surgery, outcomes improve significantly. Studies have shown that adding a drug called oxaliplatin to standard chemotherapy with fluorouracil increases three-year disease-free survival rates. In one large trial, 72% of patients receiving the combination of fluorouracil, leucovorin, and oxaliplatin were disease-free at three years, compared to 65% of those who received fluorouracil and leucovorin alone. Another study reported even higher three-year disease-free survival rates of 76% with the oxaliplatin combination compared to 72% without it^[6].

Five-year survival rates are another commonly used measure. Research indicates that adjuvant chemotherapy after surgery for stage III colon cancer is associated with a 30% increase in five-year survival rates compared to surgery alone^[18].

However, not everyone with stage III cancer has the same outlook. The subcategory of stage III matters: patients with stage IIIA generally have better outcomes than those with stage IIIC, which represents more extensive spread within the local area. Additionally, individual factors such as age, overall health, and the ability to tolerate and complete treatment influence survival^[11].

It’s also worth noting that survival statistics are based on large groups of people and reflect outcomes from previous years. Advances in treatment continue to improve survival rates, and participating in clinical trials may offer access to newer therapies that could further enhance outcomes.

#1 Clinical Trials Search in Europe